Additionally, evaluation for the value of GDF15 in lung cancer chemotherapeutic response showed that GDF15 levels were significantly decreased in all patients after two cycles of treatment, regardless of the type of response to treatment; the effect was greater in the PR group (Deng et al. 2021). This evidence concerns the gene GDF15 and lung carcinoma.